AMGN vs Peers Stock Comparison

Amgen Prices as of Oct 26, 2026 Peers: Industry group
AMGN Amgen Inc
$444.63 +7.2% 1M +52.4% 1Y
Market cap
$240.41B
P/E
27.5x
Revenue (TTM)
$38.10B
Div. yield
0.02%
Biotechnology Healthcare

Percentile Scorecard

AMGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGN
Valuation 85 #94 of 626
Growth 61 #234 of 604
Profitability 94 #33 of 555
Financial Health 22 #512 of 658
Shareholder Returns 68 #117 of 368
Overall 66
  • AMGN ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNSPY
1 month +7.2% -0.8%
3 months +18.2% +3.5%
6 months +30.7% +7.0%
Year to date +35.8% +12.2%
1 year +52.4% +13.0%
3 years +70.0% +86.3%
3 years, per year +19.4% +23.1%
5 years +115.2% +68.6%
5 years, per year +16.6% +11.0%
10 years +179.7% +258.0%
10 years, per year +10.8% +13.6%

Risk

MeasureAMGNSPY
Volatility, 1Y 29.7% 12.7%
Downside volatility, 1Y 27.9% 12.7%
Beta vs S&P 500, 1Y 0.45 1.00
Return / volatility, 1Y 1.76 1.02
Max drawdown, 5Y -26.7% -25.4%
From 52-week high -0.6% -1.8%
52-week high $447.28 $779.14
52-week low $291.16 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGN
P/E now vs peer median 27.5xmedian 17.1x
P/S now vs peer median 6.3xmedian 8.8x
EV/EBITDA now vs peer median 17.6xmedian 17.1x
P/FCF now vs peer median 23.6xmedian 18.0x
P/B now vs peer median 20.6xmedian 2.1x
PEG now vs peer median 10.36median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGN
Revenue $38.10B
Gross profit $26.48B
Operating income $11.43B
Net income $8.74B
Free cash flow $10.18B
R&D $7.63B
EPS (diluted) $16.07
Cash & equivalents $13.99B
Total debt $57.30B
Shares (diluted) 544.00M
Enterprise value $195.81B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGN
P/E 27.5x
P/FCF 23.6x
P/Operating cash flow 19.3x
P/S 6.3x
P/B 20.6x
P/Tangible book -27.3x
EV/EBITDA 17.6x
EV/EBIT 24.8x
EV/Revenue 7.4x
EV/FCF 27.9x
EV/Operating cash flow 22.7x
PEG (3Y EPS CAGR) 10.36

Growth

14 metrics
MetricAMGN
Revenue growth (1Y) 9.1%
Revenue CAGR (3Y) 12.7%
Gross profit growth (1Y) 17.6%
Gross profit CAGR (3Y) 10.3%
Operating income growth (1Y) 39.5%
Operating income CAGR (3Y) 6.4%
Net income growth (1Y) 32.1%
Net income CAGR (3Y) 3.1%
EPS growth (1Y) 31.4%
EPS CAGR (3Y) 2.7%
Operating cash flow growth (1Y) 3.9%
Operating cash flow CAGR (3Y) 4.9%
Free cash flow growth (1Y) -4.1%
Free cash flow CAGR (3Y) 1.7%

Profitability

14 metrics
MetricAMGN
Gross margin 69.5%
EBITDA margin 42.2%
Operating margin 30.0%
Pretax margin 27.0%
Net margin 23.0%
FCF margin 26.7%
Operating cash flow margin 32.8%
Return on equity 83.8%
Return on assets 9.3%
Return on invested capital 14.3%
Return on capital employed 16.7%
Asset turnover 0.4x
Cash conversion (OCF / net income) 1.4x
Stock comp / revenue 1.3%

Financial Health

11 metrics
MetricAMGN
Debt / assets 59.9%
Debt / equity 4.9x
Net debt / EBITDA 2.7x
Debt / FCF 5.6x
Liabilities / assets 87.8%
Equity / assets 12.2%
Interest coverage 4.3x
Current ratio 1.4x
Quick ratio 0.9x
Cash ratio 0.5x
Altman Z-score 2.30

Shareholder Returns

7 metrics
MetricAMGN
Dividend yield 2.2%
Net buyback yield –
Shareholder yield 2.2%
Payout ratio (earnings) 60.4%
Payout ratio (FCF) 51.9%
Dividend growth (1Y) 6.3%
Dividend CAGR (3Y) 6.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGN
Forward P/E 20.4xFY2026
EPS, next fiscal year $21.81FY2026
EPS growth, next FY -0.1%FY2026
EPS growth, the year after +7.2%
Revenue, next fiscal year $41.51BFY2026
Revenue growth, next FY +12.9%FY2026
Revenue growth, the year after +2.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGN
Held by institutions 82.7%
Institutions holding 3,159
Change in shares held, QoQ +4.5%
Institutions buying 1,451
Institutions selling 1,217
Buyers to sellers 1.19

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.